Shuai Li

Shuai Li is the Senior Director of Business Development at Biohaven Pharmaceuticals, a role she has held since July 2021. She initially joined Biohaven in November 2017 as a Manager in Business Development and Corporate Strategy. In her current position, she is responsible for driving strategic initiatives and partnerships that support the company's growth in the pharmaceutical sector.

Educational Background

Shuai Li holds a Ph.D. from Harvard University, where her research focused on small molecule drug development, specifically targeting interactions critical for leukemia initiation and immunosuppression. She also earned a dual Bachelor of Science degree in Chemistry & Biology and Economics from Tsinghua University.

Professional Experience

Prior to her tenure at Biohaven, Shuai worked at IBM as a Managing Strategy Consultant, where she utilized data analytics to solve business challenges. She has also been involved with healthcare investment advising groups, conducting market and scientific due diligence on early-stage biotechnology companies. Additionally, Shuai has passed Level III of the Chartered Financial Analyst (CFA) exam, showcasing her expertise in financial analysis within the healthcare sector.

Skills and Certifications

Shuai is recognized for her skills in business development and strategy consulting, supported by certifications from IBM, including IBM Design Thinking Practitioner and IBM Agile Explorer.

Shuai Li's diverse background in both scientific research and business strategy positions her as a key player in the pharmaceutical industry, particularly in developing innovative solutions for drug development and market strategy.